Digital mammography: a review of technical development and clinical applications.

Abstract:

:For detecting and diagnosing breast cancer at its earliest stage, mammography is the most sensitive technique currently available and is therefore the method of choice. Screen-film mammography has been used successfully as a screening test for breast cancer for > 2 decades. However, conventional mammography has substantial limitations and, therefore, digital mammography systems have been developed to improve image quality and overcome the limitations of screen-film technique limitations. Herein we discuss the differences between screen-film and digital mammography systems and the processes related to digital mammography that differ from conventional mammography, including detector technology, digital image formation, image processing, image display, and image archival. Finally, we review the results from currently available clinical trials regarding the performance of digital mammography and discuss clinical implications such as cost-effectiveness.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Shah AJ,Wang J,Yamada T,Fajardo LL

doi

10.3816/cbc.2003.n.013

keywords:

subject

Has Abstract

pub_date

2003-04-01 00:00:00

pages

63-70

issue

1

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)70445-1

journal_volume

4

pub_type

杂志文章,评审
  • Mammography Coverage and Tumor Stage in the Opportunistic Screening Context.

    abstract:INTRODUCTION:The increment of breast cancer screening coverage should lead to an increase in the proportion of early tumors diagnosed and the decrease of the cancer-related mortality. However, the effectiveness of opportunistic mammography screening is not well documented for public health systems in middle-income coun...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2019.04.014

    authors: Magario MB,Poli-Neto OB,Tiezzi DG,Angotti Carrara HH,Moreira de Andrade J,Candido Dos Reis FJ

    更新日期:2019-12-01 00:00:00

  • Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

    abstract:BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3816/CBC.2009.n.008

    authors: Vogel VG,Qu Y,Wong M,Mitchell B,Mershon JL

    更新日期:2009-02-01 00:00:00

  • The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08).

    abstract:BACKGROUND:Despite margin-negative breast-conserving surgery (BCS), phyllodes tumors (PT) of the breast show high local recurrence (LR) rates. In this study we aimed to assess the site and grade of LR to identify high-risk patients after initial treatment of malignant and borderline PT using BCS alone. PATIENTS AND ME...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clbc.2019.04.003

    authors: Choi N,Kim K,Shin KH,Kim Y,Moon HG,Park W,Choi DH,Kim SS,Ahn SD,Kim TH,Chun M,Kim YB,Kim S,Choi BO,Kim JH

    更新日期:2019-10-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract:BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2015.04.008

    authors: Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期:2015-12-01 00:00:00

  • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.

    abstract:BACKGROUND:We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer in Japan remains unclear. PATIENTS AND METHODS:The study subjects were female patients with primary unilateral invasive breast cancer considered as candidates for breast-conserving surgery w...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.08.004

    authors: Inuzuka M,Watanabe C,Yokoyama S,Kuwayama T,Akashi-Tanaka S,Arai M,Nakamura S,Registration Committee of the Japanese HBOC consortium.

    更新日期:2020-08-20 00:00:00

  • Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.

    abstract:BACKGROUND:To date, there have been no analyses to assess factors that influence post-mastectomy radiation therapy (PMRT) utilization in invasive lobular carcinoma (ILC) or to quantify the benefit of PMRT in ILC as compared with invasive ductal carcinoma (IDC). We compared histology-specific utilization of PMRT by tumo...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.02.001

    authors: Stecklein SR,Shen X,Mitchell MP

    更新日期:2016-08-01 00:00:00

  • Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.

    abstract:PURPOSE:We investigated the efficacy and toxicity of sorafenib, a multikinase inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in combination with vinorelbine therapy in a phase I/II trial in patients with metastatic breast cancer. PATIENTS AND METHODS:We enrolled 11 patients in the phase I po...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2013.10.013

    authors: Luu T,Frankel P,Chung C,Chow W,Mortimer J,Hurria A,Somlo G

    更新日期:2014-04-01 00:00:00

  • Does the result of completion axillary lymph node dissection influence the recommendation for adjuvant treatment in sentinel lymph node-positive patients?

    abstract:OBJECTIVE:The Hungarian National Institute of Oncology has just closed a single-center randomized clinical study. The Optimal Treatment of the Axilla-Surgery or Radiotherapy (OTOASOR) trial compares completion axillary lymph node dissection (cALND) with regional nodal irradiation (RNI) in patients with sentinel lymph n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clbc.2013.04.004

    authors: Sávolt A,Polgár C,Musonda P,Mátrai Z,Rényi-Vámos F,Tóth L,Kásler M,Péley G

    更新日期:2013-10-01 00:00:00

  • The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.

    abstract:BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2011.n.006

    authors: Itakura K,Lessing J,Sakata T,Heinzerling A,Vriens E,Wisner D,Alvarado M,Esserman L,Ewing C,Hylton N,Hwang ES

    更新日期:2011-03-01 00:00:00

  • Advances in radiation treatments of breast cancer.

    abstract::During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.002

    authors: Frank SJ,McNeese MD,Strom EA,Perkins G,Salehpour M,Schechter N,Buchholz TA

    更新日期:2004-02-01 00:00:00

  • Assessing Changes in the Activity Levels of Breast Cancer Patients During Radiation Therapy.

    abstract:BACKGROUND:Radiation therapy (RT) is often delivered after lumpectomy for women with breast cancer. A common perceived side effect of RT is fatigue, yet its exact effect on activity levels and sleep is unknown. In this study we analyzed the change in activity levels and sleep using an activity tracking device before, d...

    journal_title:Clinical breast cancer

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.clbc.2017.08.009

    authors: Champ CE,Ohri N,Klement RJ,Cantor M,Beriwal S,Glaser SM,Smith RP

    更新日期:2018-02-01 00:00:00

  • Physical Exercise Positively Influences Breast Cancer Evolution.

    abstract::Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2017.05.003

    authors: Adraskela K,Veisaki E,Koutsilieris M,Philippou A

    更新日期:2017-10-01 00:00:00

  • Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer.

    abstract::Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2003.n.030

    authors: Truong MT,Hirsch AE,Formenti SC

    更新日期:2003-10-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract:BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2020.09.014

    authors: Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期:2020-10-06 00:00:00

  • Cysteine rhenium colloid: a novel radiocolloid for identifying sentinel lymph nodes in breast cancer surgery.

    abstract:BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.07.006

    authors: Kidane B,Zabel PL,Gupta V,Whiston C,Wright F,Brackstone M

    更新日期:2015-02-01 00:00:00

  • Family-building After Breast Cancer: Considering the Effect on Adherence to Adjuvant Endocrine Therapy.

    abstract::Adherence to endocrine therapy (ET) is a longstanding problem in breast cancer (BC) survivorship care, particularly among younger women. Younger patients have reported lower ET initiation rates and greater rates of early discontinuation and are considered an "at risk" group for nonadherence. For women who hope to have...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2016.12.002

    authors: Benedict C,Thom B,Teplinsky E,Carleton J,Kelvin JF

    更新日期:2017-06-01 00:00:00

  • Management and Outcomes in Metaplastic Breast Cancer.

    abstract::Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic, immunohistochemical, and molecular features. Resistance to systemic therapies, whether chemotherapy or hormonal therapy, is among its main characteristics, which in turn explains the poor prognosis and renders its manage...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.clbc.2016.06.002

    authors: Tzanninis IG,Kotteas EA,Ntanasis-Stathopoulos I,Kontogianni P,Fotopoulos G

    更新日期:2016-12-01 00:00:00

  • Breast Reconstruction Actualized in Nipple-sparing Mastectomy and Direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results.

    abstract:BACKGROUND:Implant-based breast reconstruction after nipple-sparing mastectomy has been the most common breast reconstruction procedure performed, for both breast cancer treatment and prophylactically. Subpectoral implant placement with partial detachment of the pectoralis major muscle has been the procedure of choice ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2018.12.015

    authors: de Vita R,Buccheri EM,Villanucci A,Pozzi M

    更新日期:2019-04-01 00:00:00

  • Taxanes and capecitabine in combination: rationale and clinical results.

    abstract::The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2002.n.004

    authors: Maher JF,Villalona-Calero MA

    更新日期:2002-01-01 00:00:00

  • Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.

    abstract::Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2001.s.003

    authors: Pegram MD,O'Callaghan C

    更新日期:2001-10-01 00:00:00

  • Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.

    abstract:INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2014.09.012

    authors: Nagar H,Boothe D,Ginter PS,Sison C,Vahdat L,Shin S,Smith M,Chao KS,Nori D,Hayes MK

    更新日期:2015-04-01 00:00:00

  • Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

    abstract::Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/CBC.2005.n.014

    authors: Gordon DH

    更新日期:2005-06-01 00:00:00

  • Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.

    abstract:BACKGROUND:Adjuvant trastuzumab improves relapse-free survival in HER2-overexpressing breast cancer but is associated with cardiac toxicity. This phase II study was undertaken to determine the neoadjuvant clinical and pathologic response rate and the acute and chronic cardiac toxicity of trastuzumab given with weekly p...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2006.n.035

    authors: Kelly H,Kimmick G,Dees EC,Collichio F,Gatti L,Sawyer L,Ivanova A,Dressler L,Graham ML,Carey LA

    更新日期:2006-08-01 00:00:00

  • Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.

    abstract:UNLABELLED:This is a retrospective study on 40 breast cancer patients, of which 20 have bone metastases, 10 have visceral metastases, and 10 have no evidence of disease, aimed at evaluating the role of CXCR4 and the RANK/RANKL/OPG system to predict bone metastases. CXCR4 expression, alone or in combination with RANK, i...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2011.05.001

    authors: Ibrahim T,Sacanna E,Gaudio M,Mercatali L,Scarpi E,Zoli W,Serra P,Ricci R,Serra L,Kang Y,Amadori D

    更新日期:2011-12-01 00:00:00

  • Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic.

    abstract:BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2012.01.004

    authors: Vicini F,Shah C,Lyden M,Whitworth P

    更新日期:2012-04-01 00:00:00

  • Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations.

    abstract::Women with germline mutations in BRCA1 or BRCA2 are known to be at substantially elevated risk for breast cancer. With increasing acceptance of genetic testing, significant numbers of mutation carriers are being identified, but evidence-based guidelines for the management of women at hereditary risk are lacking. This ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章,评审

    doi:10.3816/cbc.2004.n.029

    authors: Robson M

    更新日期:2004-10-01 00:00:00

  • Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

    abstract:BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2010.n.061

    authors: Irvin WJ Jr,Orlowski RZ,Chiu WK,Carey LA,Collichio FA,Bernard PS,Stijleman IJ,Perou C,Ivanova A,Dees EC

    更新日期:2010-12-01 00:00:00

  • Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

    abstract:INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.1016/j.clbc.2017.10.012

    authors: Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

    更新日期:2018-04-01 00:00:00

  • Primary pure squamous cell carcinoma of the breast.

    abstract::Primary squamous cell carcinoma (SCC) of the breast is an extremely rare tumor. It is diagnosed when the malignant cells are entirely of squamous type, the tumor is independent from overlying skin, and other primary SCC sites are excluded. This report presents clinical, radiologic, and histologic correlative findings ...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2005.n.030

    authors: Siegelmann-Danieli N,Murphy TJ,Meschter SC,Stein ME,Prichard J

    更新日期:2005-08-01 00:00:00

  • Use of multiple drains after mastectomy is associated with more patient discomfort and longer postoperative stay.

    abstract:BACKGROUND:Seromas constitute a common complication following surgery for breast cancer, and closed drainage is used routinely to reduce its incidence. The aim of this study was to evaluate the influence of number of drains on patient discomfort, seroma formation, and hospital stay during the immediate postoperative pe...

    journal_title:Clinical breast cancer

    pub_type: 杂志文章

    doi:10.3816/CBC.2009.n.041

    authors: Saratzis A,Soumian S,Willetts R,Rastall S,Stonelake PS

    更新日期:2009-11-01 00:00:00